627 Kazakh citizens want to participate in clinical trials of domestic COVID-19 vaccine
627 Kazakh citizens expressed the desire to take part in clinical trials of a domestic vaccine against COVID-19, created by scientists from the Research Institute for Biological Safety Problems. Among the first volunteers are seven developers of the medicine, headed by the Director General of the institute Kunsulu Zakarya. She said that the recruitment of candidates will continue until September 10.
“We plan to select 44 people for the first phase, 200 for the second. We are pleased with the increased vaccine awareness, positive motivation and patriotism of Kazakh citizens. Such trust is not only support of the cause, but also a great moral support for us, developers, and for all science in Kazakhstan. Each of these 627 people, even if not all of them will be selected as a volunteer, as the youth say, is our hero. We are very grateful to them for such a personal contribution to the preservation of the health and safety of all people in Kazakhstan,” said Kunsulu Zakarya.
Research of the coronavirus vaccine developed by the Research Institute for Biological Safety Problems will be conducted at the National Scientific Center of Phthisiopulmonology. Kazakh citizens aged from 18 to 50 years old with excellent health can become volunteers. The domestic medicine was included in the list of candidate vaccines admitted for clinical trials by the World Health Organization on July 31. A total of 33 vaccine candidates from 19 countries are currently at the stage of clinical trials.